Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, shared on X:
Excellent insights shared by Tony Mok, on the global impact of cancer drug development in China at the inaugural GBAICTI CARE conference in Hong Kong.
A very efficient and effective drug development purpose built ecosystem has been built within a decade.”
Presentation Summary
What happened?
- Chinese government mandated to reform the biotech/pharmaceutical industry in 2009
- Improvement in regulatory time-line
- Supported by mobile China-USA talents, large scale CDRMO, effective clinical trial groups…etc
Global impact
- Significant increase in number of clinical trials
- Low cost domestic anti-cancer drugs
- Multiple successful out-licensing but future global cost may depend on regulatory ecosystem
Next 5 years
- Multiple read out multi-national studies on out-licensed drugs
- Gold rush on Chinese innovation continues
- Early signal generation from China
Other articles from Herbert Loong on OncoDaily.
